TECHNODRUG Techno Drugs Ltd.
Pharmaceuticals & Chemicals
Tk 35.5 as of 2026-11-12 14:07:07
Rank 100 of all scored
Data completeness 100%
Data completeness 100%
Score breakdown
Consistency 72
Profitability 33
Solvency 84
Valuation 48
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Valuation Trades near book value (P/NAV 1.12x)
Concerns
- Profitability Average ROE only 7.55% (below 10%: capital not working hard)
- Valuation P/E 23.51 is high (above 20)
Notes
- Consistency EPS rose in 1 of 2 years (mixed)
- Solvency Debt/equity 0.52x (well managed)
Risk flags
- Mid cap (Tk 200-1,000 cr)
Valuation
P/E
P/E audited
P/E current
P/B
NAV per share
EPS (last audited year)
Graham fair value
Margin of safety
52-week range
40.9% above the low, 31.7% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
ROE
ROE avg
ROE min
Profit CAGR
Profit YoY
Net profit
EPS up
Loss years (last ~5)
Dividends and safety
Div years
Dividend yield
Payout
Cash div
D/E
Loans/MCap
Size, liquidity and ownership
MCap
Free float
Daily turnover
Sponsor %
Inst. %
Public %
Foreign %
Shareholding
- Sponsor/director 62.7%
- Institution 5.5%
- Public 31.8%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2023 | 2.08 | 27.74 | 20 | — | — |
| 2024 | 2.94 | 33.5 | 28 | 12 | 0 |
| 2025 | 1.76 | 30.58 | 23 | 10 | 0 |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 46.3%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.